Cardiol Therapeutics Inc. (CRDL)

$1.27

+0.01 (+0.79%)
Rating:
Recommendation:
-
Symbol CRDL
Price $1.27
Beta 1.056
Volume Avg. 0.30M
Market Cap 78.649M
Shares () -
52 Week Range 1.0-4.96
1y Target Est -
DCF Unlevered CRDL DCF ->
DCF Levered CRDL LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity -
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CRDL news


Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.